{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/26940"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/26940","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"TAC Engineered γδ T cells for Multiple Myeloma","abstract":"Engineered T cell therapies have had unprecedented success in treating hematological malignancies. However, their use is limited by expensive treatment costs – priced at approximately $500,000 CAD for a single-dose of CAR-T cell therapy. γδ T cells are a candidate for allogeneic engineered T cell therapies, which can be mass manufactured to reduce the cost of goods. In this thesis we investigate γδ T cells engineered with a T cell Antigen Coupler targeting BCMA (BCMA-TAC) for the treatment of Multiple Myeloma – an incurable hematological malignancy. We optimized a manufacturing method to transduce γδ T cells with a GaLV-pseudotyped γ-retrovirus encoding BCMA-TAC and demonstrated that BCMA-TAC γδ T cells rapidly and specifically kill Multiple Myeloma tumour cells. We also investigated the potential for a combination therapy using engineered γδ T cells and monoclonal antibodies. Such a combination therapy may be synergistic, because γδ T cells express CD16 and can respond to antibody opsonized cells via direct cytotoxicity or phagocytosis. While degranulation of BCMA-TAC γδ T cells was enhanced by CD16 stimulation, we did not observe any improvements in direct cytotoxicity against antibody-opsonized tumour cells. Overall, our results demonstrate that BCMA-TAC γδ T cells can directly target and kill Multiple Myeloma tumour cells, but whether monoclonal antibodies can be used to further enhance their anti-tumour properties remains unclear.","abstract_html":"Engineered T cell therapies have had unprecedented success in treating hematological malignancies. However, their use is limited by expensive treatment costs – priced at approximately $500,000 CAD for a single-dose of CAR-T cell therapy. γδ T cells are a candidate for allogeneic engineered T cell therapies, which can be mass manufactured to reduce the cost of goods. In this thesis we investigate γδ T cells engineered with a T cell Antigen Coupler targeting BCMA (BCMA-TAC) for the treatment of Multiple Myeloma – an incurable hematological malignancy. We optimized a manufacturing method to transduce γδ T cells with a GaLV-pseudotyped γ-retrovirus encoding BCMA-TAC and demonstrated that BCMA-TAC γδ T cells rapidly and specifically kill Multiple Myeloma tumour cells. We also investigated the potential for a combination therapy using engineered γδ T cells and monoclonal antibodies. Such a combination therapy may be synergistic, because γδ T cells express CD16 and can respond to antibody opsonized cells via direct cytotoxicity or phagocytosis. While degranulation of BCMA-TAC γδ T cells was enhanced by CD16 stimulation, we did not observe any improvements in direct cytotoxicity against antibody-opsonized tumour cells. Overall, our results demonstrate that BCMA-TAC γδ T cells can directly target and kill Multiple Myeloma tumour cells, but whether monoclonal antibodies can be used to further enhance their anti-tumour properties remains unclear.","abstract_has_math":false,"creators":["Asbury, Sarah"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Biochemistry and Biomedical Sciences","school":null,"contributors":[],"advisors":["Bramson, Jonathan"],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021","date_published":"2021","updated_at":"2026-11-18T19:31:33Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/10027"],"render_values":[{"text":"https://doi.org/10.71548/10027","href":"https://doi.org/10.71548/10027","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/26940","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/26940","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F26940","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bramson, Jonathan"]},{"key":"dc:contributor.department","label":"Department","values":["Biochemistry and Biomedical Sciences"]},{"key":"dc:creator","label":"Author","values":["Asbury, Sarah"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2021-09-30T15:30:52Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2021-09-30T15:30:52Z"]},{"key":"dc:date.issued","label":"Date","values":["2021"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/26940","https://doi.org/10.71548/10027"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Engineered T cell therapies have had unprecedented success in treating hematological malignancies. However, their use is limited by expensive treatment costs – priced at approximately $500,000 CAD for a single-dose of CAR-T cell therapy. γδ T cells are a candidate for allogeneic engineered T cell therapies, which can be mass manufactured to reduce the cost of goods. In this thesis we investigate γδ T cells engineered with a T cell Antigen Coupler targeting BCMA (BCMA-TAC) for the treatment of Multiple Myeloma – an incurable hematological malignancy. We optimized a manufacturing method to transduce γδ T cells with a GaLV-pseudotyped γ-retrovirus encoding BCMA-TAC and demonstrated that BCMA-TAC γδ T cells rapidly and specifically kill Multiple Myeloma tumour cells. We also investigated the potential for a combination therapy using engineered γδ T cells and monoclonal antibodies. Such a combination therapy may be synergistic, because γδ T cells express CD16 and can respond to antibody opsonized cells via direct cytotoxicity or phagocytosis. While degranulation of BCMA-TAC γδ T cells was enhanced by CD16 stimulation, we did not observe any improvements in direct cytotoxicity against antibody-opsonized tumour cells. Overall, our results demonstrate that BCMA-TAC γδ T cells can directly target and kill Multiple Myeloma tumour cells, but whether monoclonal antibodies can be used to further enhance their anti-tumour properties remains unclear."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["TAC Engineered γδ T cells for Multiple Myeloma"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bramson, Jonathan"],"dc:contributor.department":["Biochemistry and Biomedical Sciences"],"dc:creator":["Asbury, Sarah"],"dc:date.accessioned":["2021-09-30T15:30:52Z"],"dc:date.available":["2021-09-30T15:30:52Z"],"dc:date.issued":["2021"],"dc:description.abstract":["Engineered T cell therapies have had unprecedented success in treating hematological malignancies. However, their use is limited by expensive treatment costs – priced at approximately $500,000 CAD for a single-dose of CAR-T cell therapy. γδ T cells are a candidate for allogeneic engineered T cell therapies, which can be mass manufactured to reduce the cost of goods. In this thesis we investigate γδ T cells engineered with a T cell Antigen Coupler targeting BCMA (BCMA-TAC) for the treatment of Multiple Myeloma – an incurable hematological malignancy. We optimized a manufacturing method to transduce γδ T cells with a GaLV-pseudotyped γ-retrovirus encoding BCMA-TAC and demonstrated that BCMA-TAC γδ T cells rapidly and specifically kill Multiple Myeloma tumour cells. We also investigated the potential for a combination therapy using engineered γδ T cells and monoclonal antibodies. Such a combination therapy may be synergistic, because γδ T cells express CD16 and can respond to antibody opsonized cells via direct cytotoxicity or phagocytosis. While degranulation of BCMA-TAC γδ T cells was enhanced by CD16 stimulation, we did not observe any improvements in direct cytotoxicity against antibody-opsonized tumour cells. Overall, our results demonstrate that BCMA-TAC γδ T cells can directly target and kill Multiple Myeloma tumour cells, but whether monoclonal antibodies can be used to further enhance their anti-tumour properties remains unclear."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/26940","https://doi.org/10.71548/10027"],"dc:language.iso":["en"],"dc:title":["TAC Engineered γδ T cells for Multiple Myeloma"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:31:33Z"}